source
- Merck signs up to $2.13 billion deal with SciBrunch for preclinical KRAS inhibitor SPR2015Merck announced it has completed a deal with Chinese biotech SciBrunch Therapeutics, paying $400 million upfront for exclusive global rights to develop, manufacture and commercialize SciBrunch’s pr…
- Nonprofits launch ultra-rare immune disease gene therapy Waskyra at $3.25 million priceTwo nonprofit organizations have received FDA approval for a gene therapy that targets an ultra-rare immune disorder. The therapy, called Waskyra, is now being launched with a list price of $3.25…